[HTML] sciencedirect.com

[HTML][HTML] Frontline therapy with bendamustine and rituximab (BR) in follicular lymphoma: prognosis among patients with progression of disease by 24 months (POD24) …

CL Freeman, KJ Savage, D Villa, DW Scott, AS Gerrie… - Blood, 2018 - Elsevier
Background: Bendamustine and rituximab (BR) has been a preferred regimen for frontline
therapy of patients (pts) with advanced stage follicular lymphoma (FL) since randomized …
被引用次数：8 相关文章

Frontline Therapy with Bendamustine and Rituximab (BR) in Follicular Lymphoma: Prognosis Among Patients with Progression of Disease By 24 Months (POD24) Is …

CL Freeman, KJ Savage, D Villa, DW Scott, AS Gerrie… - Blood, 2018 - ashpublications.org
Background: Bendamustine and rituximab (BR) has been a preferred regimen for frontline
therapy of patients (pts) with advanced stage follicular lymphoma (FL) since randomized …